Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

(2016) Ileana S. Mauldin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod

(2016) Richard W. Joseph et al.   MELANOMA RESEARCH

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series

(2015) Nancy Rivas-Tolosa et al.   JOURNAL OF DERMATOLOGY

100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

(2015) Vivian Y. Shi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Métastases en transit du mélanome : efficacité de l’imiquimod topique combiné au laser CO2 ou à l’électrocoagulation

(2014) F.-Z. Elfatoiki et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo

(2014) Hansje-Eva Teulings et al.   Pigment Cell & Melanoma Research

Locoregional Therapies in Melanoma

(2014) Andrea M. Abbott et al.   SURGICAL CLINICS OF NORTH AMERICA

Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis

(2013) H.E. Teulings et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma

(2013) Roger Olofsson et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Intralesional immunotherapy for melanoma

(2013) Peter Hersey et al.   JOURNAL OF SURGICAL ONCOLOGY

Laser ablation and cryotherapy of melanoma metastases

(2013) Hannah E. John et al.   JOURNAL OF SURGICAL ONCOLOGY

Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma

(2013) Diona L. Damian et al.   JOURNAL OF SURGICAL ONCOLOGY

Evolution of end points for cancer immunotherapy trials

(2012) A. Hoos   ANNALS OF ONCOLOGY

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

(2012) Marija Đorđić et al.   BMC Complementary and Alternative Medicine

Electrochemotherapy for disseminated superficial metastases from malignant melanoma

(2012) L. G. Campana et al.   BRITISH JOURNAL OF SURGERY

Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo

(2012) Nadine van Montfoort et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

(2012) C.M. Britten et al.   IMMUNITY

Combined Intralesional Bacille Calmette-Guérin (BCG) and Topical Imiquimod for In-transit Melanoma

(2012) Travis B. Kidner et al.   JOURNAL OF IMMUNOTHERAPY

Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases

(2012) Jack L. Arbiser et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy

(2011) E. P. M. Tjin et al.   CLINICAL CANCER RESEARCH

Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil

(2011) Valerie Florin et al.   INVESTIGATIONAL NEW DRUGS

Skin-Depigmenting Agent Monobenzone Induces Potent T-Cell Autoimmunity toward Pigmented Cells by Tyrosinase Haptenation and Melanosome Autophagy

(2011) Jasper G. van den Boorn et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma

(2011) Rupa Narayan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity

(2011) Jasper G. van den Boorn et al.   Pigment Cell & Melanoma Research

Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG

(2010) Jasper G. van den Boorn et al.   PLoS One

Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study

(2009) P. Quaglino et al.   ANNALS OF ONCOLOGY

Surgery and radiotherapy in the treatment of cutaneous melanoma

(2009) A. Testori et al.   ANNALS OF ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients

(2009) Jasper G. van den Boorn et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER